Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Fortress Biotech (FBIO) over the last 9 years, with Q3 2025 value amounting to $135000.0.

  • Fortress Biotech's Other Accumulated Expenses fell 8699.42% to $135000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $135000.0, marking a year-over-year decrease of 8699.42%. This contributed to the annual value of $1.5 million for FY2024, which is 82269.94% up from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Other Accumulated Expenses is $135000.0, which was down 8699.42% from $2.1 million recorded in Q2 2025.
  • Fortress Biotech's 5-year Other Accumulated Expenses high stood at $2.1 million for Q1 2025, and its period low was $135000.0 during Q3 2025.
  • Moreover, its 4-year median value for Other Accumulated Expenses was $1.0 million (2022), whereas its average is $934833.3.
  • As far as peak fluctuations go, Fortress Biotech's Other Accumulated Expenses crashed by 8797.05% in 2024, and later skyrocketed by 121349.69% in 2025.
  • Fortress Biotech's Other Accumulated Expenses (Quarter) stood at $996000.0 in 2022, then tumbled by 83.63% to $163000.0 in 2023, then surged by 822.7% to $1.5 million in 2024, then tumbled by 91.02% to $135000.0 in 2025.
  • Its last three reported values are $135000.0 in Q3 2025, $2.1 million for Q2 2025, and $2.1 million during Q1 2025.